Immune-cell PPARδ shifts the balance against colorectal tumors
PPARδ can either feed a tumor or weaken it, and the deciding factor is compartment. In Nature Immunology, investigators show that activating the lipid-sensing transcription factor inside cancer cells accelerates tumor growth, while activating it inside immune cells reverses that advantage and strengthens antitumor immunity. The finding matters because many solid tumors survive not only by growing quickly, but by forcing immune cells into metabolic exhaustion inside the tumor microenvironment.
A single pathway produced opposite effects depending on where it was switched on. In cancer cells, PPARδ promoted growth and immunosuppression; in immune cells, it improved the fitness of antitumor lymphocytes and overrode the tumor-promoting effects of cancer-intrinsic activation.
Cancer cells and T cells respond in opposite directions
The work centered on colorectal cancer, especially microsatellite stable metastatic disease, which remains resistant to checkpoint blockade and CAR T-cell approaches. Most patients with this subtype do not benefit from current immunotherapies because the tumor microenvironment suppresses infiltration, persistence, and effector function. The study framed the problem as a competition for physical space, nutrients, and transcriptional competence between malignant cells and immune cells.
To test whether PPARδ activity depends on cellular context, investigators built gain-of-function models that overexpressed a VP16/VP64–PPARδ fusion protein in either cancer cells or immune cells. When PPARδ was activated in MC38 colorectal cancer cells, tumors grew more aggressively in wild-type mice. When the same pathway was activated in immune cells through a Vav1-cre driven model, tumor growth was suppressed in both control tumors and tumors carrying cancer-cell PPARδ activation.
The shift was visible at the transcriptional and epigenomic level. Single-cell RNA sequencing and single-cell ATAC sequencing showed that cancer-intrinsic PPARδ increased expression of genes tied to survival, proliferation, and immunosuppression. In contrast, immune-intrinsic PPARδ increased expression of genes linked to apoptosis, negative regulation of proliferation, and immune recognition in tumor cells. Within CD8+ T cells, cancer-cell PPARδ activation increased expression and chromatin accessibility at dysfunction-associated loci including Ctla4, Pdcd1, Havcr2, and Lag3. When PPARδ was activated in immune cells, those exhaustion-linked programs were reduced, and the cancer-promoting effect of tumor-intrinsic PPARδ was blunted.
CD8+ T-cell fitness depends on fatty acid oxidation
Mechanistically, the study points to a metabolic route that helps CD8+ T cells keep their footing in hostile tissue. PPARδ strengthened antitumor function through effector-associated chromatin remodeling and Cpt1a-mediated fatty acid oxidation. Inside a tumor, where glucose can be scarce and suppressive metabolites are abundant, a T cell that can adapt its fuel use has a better chance of persisting long enough to kill target cells. The biology fits the phenotype: better metabolic flexibility translated into better immune activity.
That metabolic advantage was not limited to one tumor model. Immune-intrinsic PPARδ restricted growth in orthotopic Apc null, Kras G12D, Tp53 null AKP tumors, which model immune-evasive primary colorectal cancer, and in more aggressive AKPS tumors that metastasize to the liver and other sites. The same immune-programming strategy also restricted MC38 tumors, which are more immunogenic, indicating that the effect was not confined to a single genetic background.
Metastatic control improved when immune cells carried the signal
The metastatic data sharpen the clinical relevance. In the AKPS model, immune-intrinsic PPARδ dampened tumor growth, and adoptive transfer experiments showed that PPARδ-iGOF splenocytes reduced tumor burden and metastatic spread compared with wild-type splenocytes. The implication is direct: if immune cells enter the tumor with a stronger oxidative and transcriptional program, they may hold off dissemination even in an immune-evasive setting.
Parker-like contradictions in the earlier literature become easier to reconcile under a compartment-specific model. PPARδ has been reported to support tumorigenesis in cancer cells, but also to assist CD8+ T-cell memory and persistence. Those findings are not mutually exclusive once the tissue context is separated. In a tumor cell, the pathway can be pro-growth. In a T cell, the same transcription factor can reinforce cellular endurance and antitumor effector capacity.
Human co-culture experiments extended the mouse findings
The study did not stop at mouse tumors. Human colorectal cancer organoid co-cultures showed that pharmacologic PPARδ activation improved the ability of autologous immune cells to kill tumor cells. In mouse splenocyte co-culture, PPARδ activation increased lysis of MC38-luc cells. In patient-derived organoid systems, GW501516-treated peripheral blood mononuclear cells increased apoptotic signal in both microsatellite stable and microsatellite instable colorectal cancer organoids.
The MSS result deserves special attention because this is the subgroup that usually resists checkpoint blockade. A pathway that makes immune cells more competitive in that setting is especially relevant to current treatment failure. Rather than trying only to remove inhibitory brakes, the data suggest a second strategy: equip the immune compartment with the metabolic and epigenomic machinery needed to function in a suppressive niche.
CAR T cells gained function after PPARδ activation
The translational edge of the study came from human CAR T cells. Pharmacological or genetic activation of PPARδ improved CAR T-cell function and antitumor activity, suggesting that the pathway could be used as a manufacturing or ex vivo conditioning strategy before cellular therapy. For solid tumors, where CAR T cells often fail because they cannot persist or operate effectively inside the microenvironment, that kind of fitness boost could be decisive.
The work also provides a useful warning. Broad activation of PPARδ in a tumor setting would not be expected to help if the signal lands in cancer cells alone. The benefit appears to depend on directing the pathway into immune cells, where it reinforces oxidative metabolism, sustains effector states, and reduces exhaustion programs. Biology here is not symmetric. Location determines outcome.
Why the compartment matters for future therapy design
The study offers a clear therapeutic logic for immunotherapy-resistant tumors: target immune-cell metabolism without fueling the malignant compartment. In practical terms, that means future strategies will need delivery systems, cell-engineering approaches, or pharmacologic schedules that bias PPARδ activation toward T cells and away from tumor cells. The same receptor can either strengthen immunity or aid the tumor, depending on where it acts.
Several questions remain embedded in the data. The mouse models establish proof of principle, but they do not yet answer how best to direct compartment-specific activation in patients or how durable the benefit would be in established metastatic disease. The central clinical task now is to separate an immune-boosting signal from a tumor-promoting one before this biology can be carried into human treatment.